Polyplus warburg pincus
WebPolyplus ist ein französischer Anbieter innovativer Upstream-Technologien für Zell- und Gentherapien; ... einer Gesellschaft von Warburg Pincus, unterschrieben. Mit rund 270 Mitarbeiterinnen und Mitarbeitern entwickelt und produziert Polyplus Transfektions- sowie DNA- und RNA-Trägerreagenzien und Plasmid-DNA in hoher, ... WebApr 29, 2024 · 29 April 2024. Share. Warburg Pincus has made an investment in Polyplus, a developer of technology used in gene and cell therapy. Warburg’s investment in Polyplus puts the latter at a valuation ...
Polyplus warburg pincus
Did you know?
WebFeb 10, 2024 · LONDON, February 10, 2024 — Warburg Pincus, a leading global growth investor, today announced the acquisition of Pharma Intelligence, a leading provider of … WebWarburg Pincus LLC is a leading global growth investor. The firm has more than $85 billion in assets under management. The firm’s active portfolio of more than 260 companies is highly diversified by stage, sector, and geography. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable ...
WebFeb 25, 2024 · France's ArchiMed SAS agreed to sell biotechnology company Polyplus-transfection SA to fellow private equity firm Warburg Pincus LLC in a more than $500 … WebApr 29, 2024 · Warburg Pincus brings strong healthcare experience and a global network to support innovation and scale-up as Polyplus serves the gene and cell therapy market. …
WebApr 29, 2024 · Warburg Pincus’ investment alongside the existing majority shareholder, European private equity healthcare specialist ArchiMed, will advance the development and sale of Polyplus’ breakthrough solutions for the delivery of nucleic acids (transfection) for research and the biologics-based production of therapeutic drugs and vaccines. WebRuoxi Chen, Managing Director at Warburg Pincus, recently connected with PE Hub Europe to discuss the sale of Polyplus, a leading provider of innovative…
WebFeb 24, 2024 · Warburg Pincus’s bid beat out offers from competing buyout firms, the people said. Lyon-based ArchiMed acquired a majority stake in Polyplus in 2016. Polyplus develops delivery solutions for nucleic acids, like DNA and RNA, into cells. The method is used for investigating gene functions, virus production, protein delivery and gene editing.
WebPolyplus’ reagents are embedded in the majority of clinical-stage and commercially approved drugs in the rapidly growing gene therapy market. Back To ... Warburg Pincus is … cigna healthspring preferred hmo 2020WebNew York, New York, United States3K followers 500+ connections. Join to view profile. Warburg Pincus. Harvard Business School. Company Website. dhhs winning moneyWebWarburg Pincus LLC is a global private equity firm, headquartered in New York City, with offices in the United States, Europe, ... In April 2024, Warburg Pincus and ArchiMed … cigna health transportationWeb15 hours ago · Warburg Pincus has received Chinese regulatory approval to buy a 23.3% stake in Zhong Ou Asset Management Co, as the U.S. private equity giant expands its … cigna health tipsWebApr 4, 2024 · Warburg Pincus realized a 4.5x return on its recently announced sale of Polyplus, sources tell Axios exclusively. Why it matters: Exits in health care are few and … dhhs whitehallWebWarburg Pincus is proud to be ranked in the top ten in Private Equity International's PEI 300, a ranking of the world’s largest private equity firms based on… cigna health texasWebMay 29, 2024 · Warburg Pincus has more than doubled the target for its latest Asia-focused private equity fund as it joins a growing number of players bullish on South-East Asia.. The US firm is seeking $4.25 billion for Warburg Pincus China-Southeast Asia II, according to a Securities and Exchange Commission filing. dhhs women\\u0027s health branch nc